Ticker Reports for February 19th
Nebius Group: NVIDIA's Investment Sparks All-Time Highs
Shares of Nebius Group (NASDAQ: NBIS) have staged an impressive comeback, reaching new all-time highs on Friday following the disclosure that artificial intelligence and technology giant NVIDIA (NASDAQ: NVDA) has taken a position in the company. The stock soared to an intraday high of $47.68 before pulling back slightly to close at fresh record levels, gaining nearly 7% on the day.
This marks a stunning turnaround for Nebius, which had been reeling from a near 40% crash just weeks prior due to fears surrounding DeepSeek’s disruptive AI advancements.
Now up over 60% year-to-date and riding strong momentum, Nebius is seeing both price and fundamental tailwinds as major investors and corporations begin to take notice of its unique positioning in the AI infrastructure space.
NVIDIA’s Stake in Nebius: A Game-Changer?
According to its 13F filing with the SEC, NVIDIA disclosed that it had purchased nearly 1.2 million Class A shares of Nebius Group during Q4. The filing triggered a surge in investor interest, pushing the stock to record highs on Friday. This investment signals a potential endorsement of Nebius’s AI capabilities from the world’s most dominant AI chipmaker. NVIDIA’s move also suggests a belief in Nebius’s long-term potential despite the short-term volatility it has faced in recent weeks.
Nebius’s Remarkable Rebound Post-DeepSeek Disruption
Three weeks ago, Nebius stock plummeted nearly 40% following the launch of DeepSeek’s latest AI model. Investors feared that DeepSeek’s cost-efficient AI solutions would disrupt traditional AI infrastructure businesses like Nebius. However, those concerns appear to have been overstated. Since the crash, Nebius has recouped all its losses and is now trading at all-time highs, fueled by substantial corporate updates and growing institutional interest.
Nebius has continued to expand its AI services and infrastructure, positioning itself as a leader in AI deployment. Its AI-focused subsidiaries, including Toloka AI, Avride, and TripleTen, are seeing increased demand, and the company has been aggressively scaling its data center footprint.
Institutional Interest Beyond NVIDIA: Wall Street Takes Notice
While NVIDIA’s investment was the primary catalyst for Friday’s surge, it is not the only major player betting on Nebius. Several other institutional investors have recently disclosed new positions in the stock. George Soros’s Soros Capital has acquired 630,000 shares, and Marshall Wace has acquired 2.51 million shares. Columbus Hill has made NBIS its top holding, while Scoggin has also taken a new position, ranking it among its top 10 holdings.
This surge in institutional backing suggests growing confidence in Nebius’s long-term prospects and AI infrastructure capabilities.
Analyst Coverage Finally Emerging for Nebius
Following its market debut, Nebius has largely escaped analyst attention. However, that is beginning to change. On January 28, BWS Financial initiated coverage with a Buy rating and a $51 price target, citing Nebius’s strong AI positioning and proprietary infrastructure.
BWS Financial analyst Hamed Khorsand emphasized that Nebius’s AI services offer significant competitive advantages, including Toloka AI and Nebius AI. He also highlighted the company’s robust financial standing, supported by substantial cash reserves and diversified revenue streams.
What’s Next for Nebius?
With institutional interest growing, NVIDIA’s investment boosts credibility, and analysts are beginning to cover the stock. Nebius appears to be entering a new phase of market recognition.
As AI infrastructure demand expands and Nebius looks to scale its operations, the stock could see further gains. However, with the stock now at all-time highs, investors will be watching closely to see if Nebius can sustain its momentum and translate these recent developments into sustained long-term growth.
For now, NBIS appears to be not slowing down, and Wall Street is finally starting to notice.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
Trump's Return Is HUGE for Gold (His 1st Term Fueled a 57% Jump)
Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000.
Should you sit on the sideline while this is happening?
Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
Shares of the much-maligned semiconductor giant Intel (NASDAQ: INTC) have jumped over 30% in the past week as of the Feb. 18 close. This is primarily due to rumors that Intel could sell off large parts of its business to two semiconductor behemoths. President Trump reportedly planted the seed for this idea. So, is the rise in Intel shares a sign that things could be turning around for this stock, or is it driven by hopeful optimism without staying power?
Below, I’ll detail the much-talked-about rumors involving Taiwan Semiconductor Manufacturing (NYSE: TSM), Broadcom (NASDAQ: AVGO), and Intel. I’ll also shed light on comments made by Vice President JD Vance that kicked off the rally.
Breaking Down JD Vance’s Head-Turning Comments
The big rally in Intel shares started after comments made by Vance at the AI Action Summit in Paris. He made several statements supporting a deregulatory approach to artificial intelligence. However, the particularly important comment for Intel surrounded chip manufacturing.
Vance stated, "The Trump Administration will ensure that the most powerful AI systems are built in the U.S. with American-designed and manufactured chips.” This has large positive implications for Intel. Intel is essentially the only advanced-node chip manufacturer based in the United States. These are the types of chips needed for AI. TSMC and Samsung Electronics (OTCMKTS: SSNLF) are building advanced manufacturing facilities in the U.S.; however, they remain foreign companies.
Overall, if Trump wants a U.S.-based firm to manufacture advanced-node chips, Intel is really the only game in town. Still, Intel’s capabilities in this respect are currently limited.
TSMC and Broadcom Get Involved
Shares kept rising in the days that followed. The Wall Street Journal reported that Taiwan Semiconductor Manufacturing and Broadcom are both considering purchasing different parts of Intel’s business. Broadcom is “closely examining Intel’s chip-design and marketing business." It could make an offer for it, but only if another company overtakes Intel’s manufacturing arm. That is where TSMC could step in; however, the two firms are not working in concert.
For Intel, a deal of this sort would be a boon to the company. Analysts have long argued that breaking off its money-losing foundry business would add value to the rest of its business. This comes from the idea that the "sum of the parts" is more valuable than the combined Intel business. Still, there are many problems with the actual feasibility of such a deal happening.
Intel Takeover Talks: Mired in Political Hurdles and Uncertainty
First off, it's somewhat unclear what the Trump administration wants out of this deal. The consideration of such a deal by TSMC apparently came at the request of the administration. However, a White House official also said that “the president is unlikely to support a foreign entity operating Intel’s factories." It is hard to see how TSMC can make Intel competitive in AI without this happening. However, some type of “investor consortium” where TSMC invests significantly in Intel but doesn’t operate it could be an answer.
Additionally, a deal would nearly require approval from both the Chinese and United States governments. Given the tense relationship between the two countries, especially over semiconductors, this seems like a tall order.
From TSMC’s perspective, the deal would mean helping to save a floundering competitor. They value gaining favor with the United States, but is it worth risking their essential monopoly in the advanced chip manufacturing space? TSMC has more customers in the United States than in China. Still, the company wants to maintain good relationships with both countries.
For Broadcom, one analyst noted Intel’s product line could be complementary and would make the firm a leader in CPUs. It also has a strong history of integrating other companies, as demonstrated by its hugely successful purchase of VMWare. Still, acquiring Intel’s product business would likely be by far the largest transaction in the company’s history. That would be tough for a firm with $69 billion in debt and only $9 billion in cash on its balance sheet.
Overall, this remains a fluid and highly uncertain situation in my view. The Trump administration clearly wants to prop up Intel, but this deal coming together seems unlikely. However, talks are early and it could lead to something more reasonable over time. Just as Intel shares rose on these rumors, they could fall if rumors that the deal won’t happen come through. At this point, I would tend not to get too excited about the possibility of Intel’s recent surge turning into substantially more than just that.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
Elon's "New Gold"
MIT scientists just developed a brand-new metal…
A metal that's shaping up to be, not only the biggest breakthrough in artificial intelligence… but in human technology.
It's so valuable that some are referring to it as the "new gold".
Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%. So, what information came out resulting in this massive single-day rise? What potential do Wall Street analysts see in this stock, and can the appreciation continue? I’ll break all that down and provide my perspective on this small company that just saw its value explode.
SGT-003: Solid’s Answer to Duchenne Muscular Dystrophy
Solid’s leading drug candidate is SGT-003. It is a developmental medication that works to treat Duchenne Muscular Dystrophy (DMD). This is a degenerative muscular disorder that primarily affects boys, appearing typically between the ages of two and five years. A genetic mutation causes it, and it worsens progressively over time.
Solid Biosciences is working to create more potent medicines that can be used to treat this debilitating condition. This represents a huge opportunity to improve the lives of the approximately 15,000 people in the United States currently affected. In addition, it represents an opportunity to invest in a company like Solid, hoping to provide a new solution. The Food and Drug Administration (FDA) approved a drug called ELEVIDYS in 2024 that directly competes with Solid’s treatment. The $10 billion pharma company Sarepta Therapeutics (NASDAQ: SRPT) makes ELEVIDYS.
Breaking Down the Results That Sent Solid Shares Soaring
The results came from the company’s biopsy data of three participants in its Phase 1/2 INSPIRE DUCHENNE trial. When deciding whether to approve a drug, the FDA primarily looks at two factors: safety and efficacy. As of February 11, 2025, “SGT-003 has been well tolerated in the six participants dosed, with no serious adverse events observed.” This is important because Solid's past attempts at a DMD treatment were halted over safety concerns.
Efficacy data was also strong. Duchenne Muscular Dystrophy (DMD) is caused by a lack of functional dystrophin, a protein that stabilizes muscle cells. SGT-003 delivers a microdystrophin gene, which is a truncated version of dystrophin designed to reduce muscle deterioration. On average, the three patients produced more microdystrophin than healthy kids produce natural dystrophin. Other data showed comprehensive improvements in muscle strength and resilience. There were also early signs of cardiac benefits.
Breaking Down Solid’s Position and Potential of the Stock
Overall, Solid’s results were highly impressive, both in terms of safety and efficacy. Microdystrophin expression was “the highest mean expression data that has been shared to date of any Duchenne gene therapy." The company also said its medication delivered genetic material to muscles at a level five times higher than ELEVIDYS with a dose 25% lower. These data indicate that the treatment could be safer and more effective. However, seeing functional data is still extremely important.
From a financial perspective, the company has no approved drugs, and thus no revenue. Over the past four quarters, its average outflow in cash from operations has been $23 million. The company has $171 million in cash now. After issuing new shares, it will raise $200 million. So, it could have a total of $371 million in cash. This gives it a runway of four years to keep operating at this pace. However, shareholder dilution is still a significant long-term concern.
Overall, Wall Street analysts still see big upside in this stock. The average of price targets compiled by MarketBeat shows an upside in the shares of nearly 189% as of the Feb. 18 close. Analysts have yet to issue new targets after this trial data release, but it is possible they could raise their expectations significantly.
Solid Biosciences' recent results are highly encouraging for its future. However, the trial still had a very low number of patients. A larger sample size could reveal less robust results. The company aims to provide another update in Q3 with data from 10 to 12 patients. At the same time, it will look to engage the FDA in talks around an accelerated approval for SGT-003. It needs to move quickly with ELEVIDYS well on its way.
The drug brought in $384 million in revenue last quarter. Some questions surround whether ELEVIDYS patients could switch to SGT-003 without issues.
This highlights the huge opportunity Solid has if it succeeds. This is especially true if its treatment is actually safer and more effective. However, betting on the results of clinical trials can be particularly scrupulous and speculative. Shares could fall big on bad data just as they rose on good data. However, if successful, Solid may just be able to achieve the lofty valuation that Wall Street analysts see.
Where Should You Invest $1,000 Right Now?
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
MarketBeat Media, LLC dba TickerReport
345 N Reid Place, Suite 620, Sioux Falls, SD 57103.
0 Response to "🌟 Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?"
Post a Comment